Aimmune Therapeutics (AIMT) PT Raised to $60.00

Aimmune Therapeutics (NASDAQ:AIMT) had its price objective boosted by analysts at Piper Jaffray Companies from $38.00 to $60.00 in a note issued to investors on Tuesday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 69.68% from the company’s previous close.

Several other equities analysts have also issued reports on AIMT. Credit Suisse Group boosted their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a report on Wednesday, November 8th. Roth Capital assumed coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They issued a “buy” rating and a $60.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $70.00 price target (up previously from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $53.80.

Shares of Aimmune Therapeutics (AIMT) opened at $35.36 on Tuesday. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. analysts predict that Aimmune Therapeutics will post -2.54 earnings per share for the current year.

In related news, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.00, for a total value of $500,000.00. Following the sale, the insider now directly owns 20,000 shares of the company’s stock, valued at approximately $500,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stephen George Dilly sold 100,000 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total transaction of $2,501,000.00. The disclosure for this sale can be found here. Insiders sold a total of 274,986 shares of company stock worth $7,533,100 over the last ninety days. 24.56% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC lifted its position in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares in the last quarter. Teachers Advisors LLC lifted its position in Aimmune Therapeutics by 2.6% during the 1st quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after buying an additional 1,120 shares in the last quarter. Legal & General Group Plc lifted its position in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares in the last quarter. American International Group Inc. lifted its position in Aimmune Therapeutics by 8.1% during the 3rd quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock worth $585,000 after buying an additional 1,764 shares in the last quarter. Finally, Strs Ohio lifted its position in Aimmune Therapeutics by 6.1% during the 2nd quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock worth $711,000 after buying an additional 2,000 shares in the last quarter. 73.34% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics (AIMT) PT Raised to $60.00” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/07/aimmune-therapeutics-aimt-pt-raised-to-60-00.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

What are top analysts saying about Aimmune Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit